D
Deborah Donnell
Researcher at Fred Hutchinson Cancer Research Center
Publications - 231
Citations - 13344
Deborah Donnell is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Pre-exposure prophylaxis & Population. The author has an hindex of 49, co-authored 199 publications receiving 11097 citations. Previous affiliations of Deborah Donnell include University of California, Los Angeles & University of Washington.
Papers
More filters
Journal ArticleDOI
Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection.
Susan H. Eshleman,Marla Husnik,Sarah E. Hudelson,Deborah Donnell,Yijian Huang,Wei Huang,Stephen Hart,Brooks Jackson,Thomas J. Coates,Margaret A. Chesney,Beryl A. Koblin +10 more
TL;DR: Antiretroviral drug resistance is relatively common among recently infected men who have sex with men in the United States, and there is no statistically significant association with demographic factors, sexual practices, self-reported sexually transmitted infections, use of recreational drugs, or use of antiret virus drug post-exposure prophylaxis.
Journal ArticleDOI
Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial
Paul K. Drain,Jienchi Dorward,Jienchi Dorward,Lauren R Violette,Justice Quame-Amaglo,Katherine K. Thomas,Natasha Samsunder,Hope Ngobese,Koleka Mlisana,Koleka Mlisana,Pravikrishnen Moodley,Pravikrishnen Moodley,Deborah Donnell,Ruanne V. Barnabas,Kogieleum Naidoo,Kogieleum Naidoo,Salim S. Abdool Karim,Salim S. Abdool Karim,Salim S. Abdool Karim,Connie Celum,Nigel Garrett,Nigel Garrett +21 more
TL;DR: Point-of-care viral load testing combined with task shifting significantly improved viral suppression and retention in HIV care and can simplify treatment and improve outcomes for HIV-positive adults receiving ART in resource-limited settings.
Journal ArticleDOI
PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
Connie Celum,Sybil Hosek,Mandisa Tsholwana,Sheetal Kassim,Shorai Mukaka,Bonnie J. Dye,Subash Pathak,Nyaradzo Mgodi,Linda-Gail Bekker,Deborah Donnell,Ethan Wilson,Krista Yuha,Peter L. Anderson,Yaw Agyei,Heather Noble,Scott Rose,Jared M. Baeten,Jessica M. Fogel,Adeola Adeyeye,Lubbe Wiesner,James F. Rooney,Sinead Delany-Moretlwe +21 more
TL;DR: In this article, the effect of drug level feedback on adherence and persistence of pre-exposure prophylaxis (PrEP) for African adolescent girls and young women (AGYW) was investigated.
Journal ArticleDOI
COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact.
David A. Swan,Chloe Bracis,Holly Janes,Mia Moore,Laura Matrajt,Daniel B. Reeves,Eileen Burns,Deborah Donnell,Deborah Donnell,Myron S. Cohen,Joshua T. Schiffer,Joshua T. Schiffer,Dobromir T. Dimitrov,Dobromir T. Dimitrov +13 more
TL;DR: In this article, the authors assess and compare the population impact of vaccines with different efficacy profiles (VESYMP and VESUSC) satisfying licensure criteria, and develop a mathematical model of SARS-CoV-2 transmission.
Journal ArticleDOI
Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083
Mark A. Marzinke,Beatriz Grinsztejn,Jessica M. Fogel,Estelle Piwowar-Manning,Maoji Li,Lei Weng,Marybeth McCauley,Vanessa Cummings,Shahnaz Ahmed,Casey D Haines,Lane R. Bushman,Christos J. Petropoulos,Deborah Persaud,Adeola Adeyeye,Ryan Kofron,Alex R. Rinehart,Marty St. Clair,James F. Rooney,Daniel Pryluka,Lara E. Coelho,Aditya H. Gaur,Keren Middelkoop,Nittaya Phanuphak,Myron S. Cohen,Craig W. Hendrix,Peter L. Anderson,Brett Hanscom,Deborah Donnell,Raphael J. Landovitz,Susan H. Eshleman +29 more
TL;DR: Marzinke et al. as discussed by the authors showed that long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV prevention in cisgender men and transgender women who have sex with men.